SKYWORKS-AERONAUTICS
15.9.2021 14:02:10 CEST | Business Wire | Press release
Today, Europcar Brazil announced plans to purchase 50 eGyro™ electrically powered vertical take-off and landing (eVTOL) aircraft from Skyworks Aeronautics (“Skyworks”) for use in Brazil, the world’s fourth largest market for civil helicopters after the U.S., Russia and Canada. Europcar is the world’s third largest rental car company and leading mobility provider.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005440/en/
“Europcar Brazil is extremely excited to partner with Skyworks Aeronautics to bring safe, efficient, and cost-effective electric aircraft solutions to Brazil,” stated Paulo Gaba, Chief Executive Officer of the Autotur Group, the Europcar franchisee for Brazil. “This initial order for Skyworks’ revolutionary eGyro reflects our understanding that though aviation certainly connects the world in important ways, we have an opportunity to deliver new, sustainable mobility capabilities that create immense value for consumers while better caring for our planet. The offer of eGyros will complete our range of possibilities as a global mobility provider,” Gaba added.
“Skyworks Aeronautics has been developing manned and unmanned vertical lift gyroplane technologies for more than two decades, providing sustained autorotative flight capabilities that enable aircraft to be both runway independent and economical, and without the physics-imposed speed, range, and payload limitations of a helicopter,” added Jack Carter, Skyworks Director. “This exciting partnership with Europcar Brazil highlights the promise of our electrified gyrocraft to expand their already extraordinary service capabilities to serve current and future markets in new, safe and exciting ways,” Carter added.
“We are living at a time of incredible opportunity and excitement as it relates to aviation,” stated John Michel, Co-Founder and Chief Executive Officer of Skyworks Aeronautics. “At a time in history where demand for the safe and efficient movement of people and goods, as well as growing desire for effective emissions-free flight converge, this partnership with Europcar Brazil allows us to work together to demonstrate the transformative impact of gyronautics in the world’s fourth largest market for civil helicopters,” Michel added. “Together, we look forward to making affordable mobility accessible to the masses in Brazil and beyond.”
About Europcar Mobility Group
EmobG is a major player in mobility markets and listed on Euronext Paris, that has recently announced an agreement with a consortium led by Volkswagen designed to drive future value creation in transforming mobility ecosystems.
Europcar Mobility Group delivers its mobility solutions worldwide through an extensive network in over 140 countries (including wholly owned subsidiaries – 18 in Europe, 1 in the USA, 2 in Australia and New Zealand – completed by franchises and partners).
About Skyworks Aeronautics
Skyworks Aeronautics is the world leader in the science and technology of gyronautics, focusing on the design and development of high-performance gyroplanes. Skyworks gyroplanes provide more affordable, safer, and higher performance alternatives for runway-independent aircraft.
Skyworks has more than 40 patents with several more underway, all obtained in an effort to radically change not only the way gyroplanes are perceived, but also the way they are utilized. From mass personnel transportation, agriculture, defense, and border protection to changing the economies of developing nations, Skyworks' goal is to change the nature of vertical flight. For more information about the company, its products, and individual members of the Skyworks team, visit www.skyworks-aero.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005440/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom